Antiemetic use and CINV-related hospitalization costs after highly or moderately emetogenic chemotherapy

Future Oncology, our partner journal, has recently published a Research Article, which explores the effect of netupitant or fosnetupitant with palonosetron on chemotherapy-induced nausea and vomiting-related hospitalization costs. Abstract: Background: Despite numerous available antiemetics, chemotherapy-induced nausea and vomiting (CINV) remains a concern, and CINV-related hospitalizations and costs often result. Materials & Methods: PrecisionQ analyzed its database to evaluate CINV-related hospitalizations and costs following antiemetics use including netupitant/fosnetupitant with palonosetron (NEPA), aprepitant/fosaprepitant with ondansetron (APON), or aprepitant/fosaprepitant with palonosetron (APPA) in patients receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC). Results: Database analysis identified 15 583 patient records (807 NEPA,...